This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Health Winners & Losers

Updated from 1:49 p.m. EDT

Despite analyst speculation and a trickle of earnings, health indices were relatively flat at the start of the week. Amgen (AMGN - Get Report) got a nudge Monday after an upgrade to outperform from market perform by Sanford C. Bernstein & Co.

Bernstein attributed the upgrade to potential restructuring. "We believe it is now inevitable that Amgen will announce a restructuring and that such an announcement could emerge within the next month, potentially even prior to the September 11 FDA advisory committee review of EPO safety in Chronic Kidney Disease (CKD)," Bernstein analysts said in a report. The stock closed up $1.18, or 2.4%, to $51.26.

Speaking of upgrades, ImClone (IMCL), which named John Johnson CEO last week, was upgraded by Cowen & Co. on Friday to neutral from underperform. ImClone stock continued to rise into this week, closing up $1.41, or 4.5%, to $32.69.

ImClone and Amgen are both components of the Nasdaq biotechnology index, which was up 1.87, or 0.2%, to 797.42 on Monday.

On the earnings side, Ziopharm Oncology (ZIOP - Get Report) posted quarterly results Monday that showed a loss of $6.5 million, or 31 cents a share, compared with a loss of $5.4 million, or 43 cents a share, in the year-ago quarter. Analysts surveyed by Thomson Financial had expected a loss of 27 cents a share.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ZIOP $11.92 0.00%
AMGN $163.58 0.00%
IMCL $3.00 0.00%
JNJ $99.58 0.00%
AAPL $124.75 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs